Skip to main content
. Author manuscript; available in PMC: 2020 Feb 12.
Published in final edited form as: Nat Med. 2019 Aug 12;25(9):1422–1427. doi: 10.1038/s41591-019-0542-z

Extended Data Fig. 5: Dual TRK and MEK blockade inhibits growth of the LOXO-195 resistant LMNA-NTRK1, NTRK1 G595R, KRAS G12D cancer cell line.

Extended Data Fig. 5:

a, Western blot from the two colorectal cancer cell lines LMNA-NTRK1, NTRK1 G595R and LMNA-NTRK1, NTRK1 G595R, KRAS G12D, treated as indicated. LOXO-195 (50nM), MEK-162 (50nM) or the combination of both drugs (195 + 162) were administered at the indicated time and protein lysates were probed with the indicated antibodies. While LOXO-195 was sufficient to inhibit both phospo-TRK and phospho-ERK in the KRAS wild type cell line, the combination of LOXO-195 and MEK-162 was required for this dual inhibition in the KRAS G12D mutated cell line. Three biological replicates were performed. b, Proliferation assays on the same cell lines (labeled NTRK1 G595R and KRAS G12D, respectively) treated for 72 hours with LOXO-195 (125nM), MEK-162 (25nM) or their combination. Data are presented as mean ± SD of four biological replicates. Two-tailed unpaired t-test was used to evaluate significant differences in % of viable cells. P values <0.05 were considered statistically significant.